Shire Shuffles Corporate Leadership: CFO Russell Rises To CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
Chairman Cavanaugh retires, to be replaced in June by former chief exec Emmens.
You may also be interested in...
For Shire, Life After Adderall XR? Yes
Shire has scaled its Adderall XR patent cliff, replenishing lost blockbuster sales with revenues from niche products, smart life-cycle management, and some good-old-fashioned luck. IN VIVO interviews CEO Angus Russell.
For Shire, Life After Adderall XR? Yes
Shire has scaled its Adderall XR patent cliff, replenishing lost blockbuster sales with revenues from niche products, smart life-cycle management, and some good-old-fashioned luck. IN VIVO interviews CEO Angus Russell.
Shire Shores Up Rare Disease Portfolio With Amicus Compounds
Deal valued at up to $440 million would give the U.K. firm three pharmacological chaperone compounds that could compete with Genzyme products in Gaucher, Fabry and Pompe diseases.